Cargando…
A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee
Background. Opioid analgesics are included in treatment guidelines for the symptomatic management of osteoarthritis (OA). Starting with a low dose of opioid and slowly titrating to a higher dose may help avoid intolerable side effects. Methods. Subjects aged ≥40 years, with moderate to severe pain i...
Autores principales: | Vojtaššák, Jozef, Jacobs, Adam, Rynn, Leonie, Waechter, Sandra, Richarz, Ute |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195291/ https://www.ncbi.nlm.nih.gov/pubmed/22110921 http://dx.doi.org/10.1155/2011/239501 |
Ejemplares similares
-
Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012) -
Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
por: Devarakonda, Krishna, et al.
Publicado: (2013) -
A new extended release formulation (OROS(®)) of hydromorphone in the management of pain
por: Weinstein, Sharon M
Publicado: (2009) -
Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study
por: Le Loët, Xavier, et al.
Publicado: (2005) -
Pharmacokinetic profile of a 24-hour controlled-release OROS(® )formulation of hydromorphone in the presence and absence of food
por: Sathyan, Gayatri, et al.
Publicado: (2007)